News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
WESTLAKE VILLAGE, Calif., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported financial results for the quarter and year ended December31, 2021, and provided a business update.
We executed exceptionally well in 2021, delivering strong Phase 3 plaque psoriasis data, initiating three additional Phase 3 programs, and commencing our commercialization efforts. We then capped off the year by receiving FDA acceptance of our NDA filing for roflumilast cream in plaque psoriasis and securing a $225 million non-dilutive loan facility to extend our cash runway into 2024, said Frank Watanabe, Arcutis President and Chief Executive Officer. We have strong momentum and expect that 2022 will be a transformational year for Arcutis, as we prepare for our first potential product launch in plaque psoriasis and progress our three additional Phase 3 topical roflumilast programs, as well as our early pipeline. With the strong team we have built and our financial flexibility enhanced, we can continue to appropriately invest in our mission to advance the treatment of chronic inflammatory skin diseases for patients and healthcare professionals.
Pipeline Updates
Roflumilast cream - a highly potent and selective phosphodiesterase-4 (PDE4) inhibitor in a once-daily cream formulation, being developed as a potential treatment for plaque psoriasis and atopic dermatitis
Roflumilast foam - an alternative once-daily foam formulation of topical roflumilast designed to overcome the challenges of delivering topical drugs in hair-bearing areas of the body, being developed as a potential treatment for seborrheic dermatitis and scalp and body psoriasis
ARQ-252- a topical small molecule inhibitor of Janus kinase type 1 (JAK1), being developed as a potential treatment for chronic hand eczema, vitiligo, and other inflammatory dermatoses
ARQ-255- an alternative topical formulation ofARQ-252designed to reach deeper into the skin in order to potentially treat alopecia areata
Recent Corporate Highlights
Fourth Quarter and Full Year 2021 Summary Financial Results
Cash, cash equivalents, restricted cash, and marketable securitieswere $388.6 million as of December31, 2021, compared to $286.0 million as of December31, 2020. Arcutis believes that its current cash, cash equivalents, and marketable securities, combined with its committed loan facility, will be sufficient to fund its operations into 2024.
Research and development (R&D) expensesfor the quarter ended December31, 2021 were $52.6 million compared to $27.4 million for the corresponding period in 2020. R&D expenses for the year ended December 31, 2021 were $145.6 million compared to $115.3 million for the corresponding period in 2020. The year-over-year increase for the quarter ended December31, 2021 was primarily due to increased clinical and manufacturing costs related to the initiation of three additional Phase 3 topical roflumilast development programs. The year-over-year increase for the year ended December 31, 2021 was primarily due to higher headcount to manage our growing clinical programs, as well as increased professional services expenses.
General and administrative (G&A) expensesfor the quarter ended December31, 2021 were $18.7 million compared to $6.7 million for the corresponding period in 2020. G&A expenses for the year ended December 31, 2021 were $61.0 million compared to $21.3 million for the corresponding period in 2020. These year-over-year increases were primarily due to higher headcount and professional services expenses as we prepare for commercialization.
Net losswas $71.3 million, or $1.42 per basic and diluted share, for the quarter ended December31, 2021 compared to $34.0 million, or $0.79 per basic and diluted share, for the corresponding period in 2020. Net loss was $206.4 million, or $4.18 per basic and diluted share, for the year ended December 31, 2021 compared to $135.7 million, or $3.80 per basic and diluted share, for the corresponding period in 2020.
About Arcutis -Bioscience, applied to the skin.
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a medical dermatology company that champions meaningful innovation to address the urgent needs of patients living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis harnesses our unique dermatology development platform coupled with our dermatology expertise to build differentiated therapies against biologically validated targets. Arcutis dermatology development platform includes a robust pipeline with multiple clinical programs for a range of inflammatory dermatological conditions, with one NDA under review with the FDA and three Phase 3 clinical data readouts anticipated by the end of 2022. The companys lead program, topical roflumilast, has the potential to advance the standard of care for plaque psoriasis, atopic dermatitis, scalp psoriasis, and seborrheic dermatitis. For more information, visitwww.arcutis.comor follow Arcutis on LinkedIn and Twitter.
Forward Looking Statements
This press release contains "forward-looking" statements, including, among others, statements regarding the potential for its topical drugs in development to address large markets with significant unmet need; expectations with regard to the timing of data and regulatory events anticipated during 2022; and the Companys belief that its current cash, cash equivalents, and marketable securities, including the net proceeds from its recent debt financing, will be sufficient to fund its operations into 2024. These statements involve substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements and you should not place undue reliance on our forward-looking statements. Risks and uncertainties that may cause our actual results to differ include risks inherent in the clinical development process and regulatory approval process, the timing of regulatory filings, the timing and expenses of commercialization efforts, and our ability to defend our intellectual property. For a further description of the risks and uncertainties applicable to our business, see the Risk Factors section of our Form10-Kfiled with U.S. Securities and Exchange Commission (SEC) on February 22, 2022, as well as any subsequent filings with the SEC. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.
Contacts:
MediaAmanda Sheldon, Head of Corporate Communicationsasheldon@arcutis.com
InvestorsEric McIntyre, Head of Investor Relationsemcintyre@arcutis.com
ARCUTIS BIOTHERAPEUTICS, INC.Condensed Balance Sheets(In thousands)
ARCUTIS BIOTHERAPEUTICS, INC.
Condensed Statements of Operations(In thousands, except share and per share data)
- Retrospective analysis of 397 DABE | CCID - Dove Medical Press - December 3rd, 2023 [December 3rd, 2023]
- Derm In The News: November 26-December 2 - Dermatology Times - December 3rd, 2023 [December 3rd, 2023]
- When is the Best Time to Try Alternative Treatments for Eczema? - National Eczema Association - September 23rd, 2023 [September 23rd, 2023]
- How Eczema Negatively Impacted the Way She Talked to Herself - National Eczema Association - September 23rd, 2023 [September 23rd, 2023]
- Colloidal Oatmeal Effective in Improving Atopic Dermatitis in Black ... - Dermatology Times - September 23rd, 2023 [September 23rd, 2023]
- Combination Treatments in HS Require Further Review - Dermatology Times - September 23rd, 2023 [September 23rd, 2023]
- Addressing Misconceptions, Concerns Around Biosimilar Use - Dermatology Times - September 23rd, 2023 [September 23rd, 2023]
- Native American and Indigenous Communities Face Dermatologic ... - Dermatology Times - September 23rd, 2023 [September 23rd, 2023]
- Microwave Therapy Successful for Treating Warts in Children - Dermatology Times - September 23rd, 2023 [September 23rd, 2023]
- 9 Best Antifungal Body Washes Review - The Jerusalem Post - September 23rd, 2023 [September 23rd, 2023]
- Patients With Severe Psoriasis Have Higher Risk of Heart Disease ... - AJMC.com Managed Markets Network - September 23rd, 2023 [September 23rd, 2023]
- Swimming and skin: What to know if a child has eczema - Harvard Health - May 20th, 2023 [May 20th, 2023]
- Experts demand traffic-light labels to show strength of eczema cream - Daily Mail - May 20th, 2023 [May 20th, 2023]
- Its mosquito season. Here are tips for treating bites, preventing them in the first place - Yahoo News - May 20th, 2023 [May 20th, 2023]
- How new EU incentives will help all patients get the best treatments - Euronews - May 20th, 2023 [May 20th, 2023]
- Consistent Use of Ceramide-Containing Products Combined With ... - Dermatology Times - May 20th, 2023 [May 20th, 2023]
- The Best Swimming Skin and Hair Products | livestrong - Livestrong - May 20th, 2023 [May 20th, 2023]
- These 13 Household Items Contain Smells That Are Harmful To ... - Rock 92.9 - May 20th, 2023 [May 20th, 2023]
- FDA Approves First Pill to Treat Moderate-to-Severe Crohn Disease - HealthDay News - May 20th, 2023 [May 20th, 2023]
- Feds investigating eczema cream after two Oregon babies found with high levels of lead in blood - OregonLive - January 27th, 2023 [January 27th, 2023]
- Heres how to treat eczema and other skin conditions for cold weather - The Hindu - January 27th, 2023 [January 27th, 2023]
- Atopic eczema - NHS - November 23rd, 2022 [November 23rd, 2022]
- Seborrheic dermatitis - Symptoms and causes - Mayo Clinic - November 23rd, 2022 [November 23rd, 2022]
- Oatmeal skincare is the perfect solution for sensitive skin (+ best products to try) - Lifestyle Asia Singapore - November 23rd, 2022 [November 23rd, 2022]
- Eczema - StatPearls - NCBI Bookshelf - October 21st, 2022 [October 21st, 2022]
- Cold, dry weather can trigger eczema - how to reduce damage to the skin this winter - Express - October 21st, 2022 [October 21st, 2022]
- Eczema on lips nhs - kved.erxe.de - August 29th, 2022 [August 29th, 2022]
- xrfkc.vitalhaskap.pl - August 29th, 2022 [August 29th, 2022]
- Atopic eczema and alopecia areata - cyasn.kugel-lernfoerderung.de - August 29th, 2022 [August 29th, 2022]
- north shore zipline oahu - owk.tophouse.shop - August 29th, 2022 [August 29th, 2022]
- nak stock - vbi.maxense.shop - August 29th, 2022 [August 29th, 2022]
- Atopic eczema and alopecia areata - zayqif.hydra-market.shop - August 29th, 2022 [August 29th, 2022]
- fort worth map with zip codes - prxrzj.rids-gear.shop - August 29th, 2022 [August 29th, 2022]
- Ear Eczema: Symptoms, Causes, and Treatments - Healthgrades - August 29th, 2022 [August 29th, 2022]
- The Mutha Body Oil Is Worth the Splurge, Especially If You Have Sensitive Skin - POPSUGAR - August 29th, 2022 [August 29th, 2022]
- Are You Allergic to Your Beauty Products? A Patch Test Might Tell You - Allure - August 29th, 2022 [August 29th, 2022]
- Stinky sweat turns out to have a surprising health benefit : Goats and Soda - NPR - August 29th, 2022 [August 29th, 2022]
- Makeup for Eczema-Prone Skin: Considerations, Products, and Tips - Healthline - July 13th, 2022 [July 13th, 2022]
- Eczema Vaccinatum: Symptoms, Diagnosis, and Treatment - Healthline - July 13th, 2022 [July 13th, 2022]
- What Is Topical Steroid Withdrawal in Atopic Dermatitis Treatment? - Everyday Health - July 13th, 2022 [July 13th, 2022]
- A new 'cure for eczema' pill has been signed off but who is allowed to take it? - Cosmopolitan UK - July 13th, 2022 [July 13th, 2022]
- What Causes Dandruff And How To Get Rid Of It, According To A Dermatologist - Fatherly - July 13th, 2022 [July 13th, 2022]
- Allergies on the rise due to climate change - BusinessWorld Online - July 13th, 2022 [July 13th, 2022]
- Cryotherapy Treatment: Uses and Benefits - newschannelnebraska.com - July 13th, 2022 [July 13th, 2022]
- Mutations of Filaggrin Leading to Eggs & Milk Allergies - Physician's Weekly - June 18th, 2022 [June 18th, 2022]
- How AI & the Pandemic Are Changing the Skin & Hair Clinic Experience - The Quint FIT - June 18th, 2022 [June 18th, 2022]
- How to treat your childs dry skin in winter - Lowvelder - June 15th, 2022 [June 15th, 2022]
- Topical steroid: Types, uses, side effects and treatment as revealed by doctors - Hindustan Times - June 15th, 2022 [June 15th, 2022]
- Psoriasis in the Belly Button: Symptoms, Causes, and Treatment - Healthline - June 15th, 2022 [June 15th, 2022]
- In his last days, my father asked for Yiddish music - Forward - June 15th, 2022 [June 15th, 2022]
- Throwing away the water after cooking rice? Know how it could benefit your skin and hair - Times Now - June 15th, 2022 [June 15th, 2022]
- Family 'devastated and numb' as boy, 9, dies a day after breaking his arm - Coventry Live - June 15th, 2022 [June 15th, 2022]
- Happy Cappy Not Just For Babies; Everyone With Sensitive Skin Can Benefit - Pediatric Shampoo Granted Trademark in New Campaign: 'No Scalp Left... - June 15th, 2022 [June 15th, 2022]
- Eczema on black skin: Pictures, symptoms, and treatment - June 11th, 2022 [June 11th, 2022]
- Eczema on the Ears or Eyebrows: How to Cope - Everyday Health - June 11th, 2022 [June 11th, 2022]
- What People With Eczema Need to Know About Self-Screening for Skin Cancer - National Eczema Association - June 11th, 2022 [June 11th, 2022]
- How to protect children with eczema from scratching until they bleed - Channel NewsAsia - June 11th, 2022 [June 11th, 2022]
- Autism, allergies and other diseases and disorders afflicted baby boomers, too - PolitiFact - June 11th, 2022 [June 11th, 2022]
- Is saltwater good for the skin? What to know Beaufort South Carolina The Island News - The Island News - June 11th, 2022 [June 11th, 2022]
- What's trending? The most-read stories on APAC beauty market and consumer insights - CosmeticsDesign-Asia.com - June 11th, 2022 [June 11th, 2022]
- Canada to require a warning be printed on every cigarette - Coventry Live - June 11th, 2022 [June 11th, 2022]
- Holistic Acne Treatments That Are Better Than What You've Been Doing - The List - June 11th, 2022 [June 11th, 2022]
- Almirall: Eight out of Ten Patients Maintained Skin Clearance at One Year in Lebrikizumab Atopic Dermatitis Monotherapy Trials - PR Newswire UK - June 7th, 2022 [June 7th, 2022]
- Woman left balding and bedbound by chronic eczema clears the condition with a 9 face cream - The Independent - June 7th, 2022 [June 7th, 2022]
- Poll: Six in 10 people would eat food that has fallen on the floor - Coventry Live - June 7th, 2022 [June 7th, 2022]
- The itch that rashes: Treating and understanding eczema - El Paso Inc. - June 5th, 2022 [June 5th, 2022]
- Celebrities With Eczema Speak Out - Everyday Health - June 5th, 2022 [June 5th, 2022]
- Lotion, Cream, Gel, and Ointment Similarly Effective for Childhood Eczema - HealthDay News - June 5th, 2022 [June 5th, 2022]
- Antibiotics Given Before C-sections Are Not Linked to Asthma, Eczema in Young Children - Pharmacy Times - June 5th, 2022 [June 5th, 2022]
- Eczema Skin-Care Products Market Size, Scope and Forecast | Alliance Pharma Plc., Bausch Health Companies Inc., Bayer AG., AbbVie Inc., Eli Lilly and... - June 5th, 2022 [June 5th, 2022]
- What are the benefits of ceramides for the skin? - Medical News Today - June 5th, 2022 [June 5th, 2022]
- Some Allergies Associated With Lower Risk of SARS-CoV-2 Infection - Smithsonian Magazine - June 5th, 2022 [June 5th, 2022]
- The CDC is sending monkeypox vaccines to people at high risk in a race to prevent the spread - CNBC - June 5th, 2022 [June 5th, 2022]
- Missing Sikeston teen may be heading to Kansas City area - KMBC Kansas City - June 5th, 2022 [June 5th, 2022]
- Should you cleanse or exfoliate first? What to know - Medical News Today - June 5th, 2022 [June 5th, 2022]
- Dry Skin: Eczema, Itchy Skin, Causes, Treatments, Relief, Types - May 17th, 2022 [May 17th, 2022]
- Foods to Eat and Foods to Avoid If You Have Eczema - The Beet - May 17th, 2022 [May 17th, 2022]
- 3 Women With Eczema Describe the Ways They Combat Nighttime Flare-Ups - Verve Times - May 17th, 2022 [May 17th, 2022]
- The Challenges of Parenting a Child With Eczema - Verve Times - May 17th, 2022 [May 17th, 2022]
- Manuka Honey Benefits for Skin: Benefits, Masks, and More - Greatist - May 17th, 2022 [May 17th, 2022]